Yubo International Biotech Limited
Symbol: YBGJ
PNK
0.325
USDMarktpreis heute
-175.4014
P/E-Verhältnis
-1.8389
PEG-Verhältnis
38.94M
MRK Kapital
- 0.00%
DIV Rendite
Yubo International Biotech Limited (YBGJ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0.4 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 0.3 | 0 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 0.8 | 1.1 | 1.9 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1.4 | 3.3 | 0.4 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0.1 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 1.6 | 3.5 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.5 | 0.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.4 | 0.8 | 0.3 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 1.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 2.9 | 4.7 | 1.3 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -3.7 | -2.5 | -0.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | 0.1 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2.9 | 2.1 | 2 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.6 | -0.1 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 0.8 | 2.7 | -1.1 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 1.2 | 0.5 | 0.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.1 | -0.2 | 0 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -0.2 | -0.1 | -0.1 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 1 | 0.6 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.8 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.1 | 0.6 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0.1 | 1.4 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.1 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -1.4 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 1.4 | 0 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0.1 | -1 | 0.1 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -1.6 | 0 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0.1 | 1.2 | 1.4 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.1 | 0.4 | 0.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0.1 | 0.8 | 1.2 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 1.3 | 2.4 | 2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1.3 | 2.8 | 2.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -1.2 | -1.5 | -0.7 |
Häufig gestellte Frage
Wie hoch ist die Yubo International Biotech Limited (YBGJ) Gesamtvermögen?
Yubo International Biotech Limited (YBGJ) Gesamtvermögen ist 2348551.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.390.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.002.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -2.586.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -2.620.
Was ist der Yubo International Biotech Limited (YBGJ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -1204765.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 790499.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 1257875.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.